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In higher eukaryotes, DNA is progressively packaged into chromatin. In these 
varying levels of compaction, linker histone H1 is a key player for mediating chromatin 
folding. As a result, linker histone H1 is involved in regulating cellular activities, such as 
gene transcription. Also essential for multiple cellular processes, topoisomerase II alpha 
(Top2a) is an enzyme that regulates DNA topology and thus is a target in cancer 
therapeutics. Previous studies in our lab have identified Top2a as an H1.3 binding partner 
by immunoprecipitation in embryonic stem cells. Further studies have shown that mouse 
histone H1.3 inhibits Top2a enzymatic activity in vitro. In this thesis, I pursued a 
functional analysis to confirm and analyze the inhibitory effect of human H1.3 on Top2a 
in vivo.  We found that overexpression of hH1.3 significantly suppressed the growth of 
HeLa cancer cells and resulted in an increased cell population with abnormal mitotic 
chromosomes. These analyses may lead to a better understanding of the role of H1 and 







Topoisomerases: An Overview 
Topological tension in DNA occurs in a variety of cellular processes, such as 
transcription, DNA replication, and chromosome segregation (Espeli & Marians, 2004; 
Larsen, Skladanowski, & Bojanowski, 1996; Luo, Yuan, Chen, & Lou, 2009; McClendon 
& Osheroff, 2007; Mondal et al., 2003; Wang, 2002). Such topological tension, when left 
unresolved, leads to DNA breaks and disruption of many cellular processes (McClendon 
& Osheroff, 2007; Wang, 2002). Topoisomerases, a group of enzymes commonly present 
in the ‘chromosome scaffold’, relax topological DNA tensions and resolve chromatin 
entanglement. Topoisomerases are classified as either type I or type II depending on their 
mechanisms in altering supercoil topology. Type I topoisomerases transiently cut a single 
DNA backbone, allowing for the rotation of the resulting sing-stranded DNA around the 
break. This process is ATP-independent. In comparison, type II topoisomerases, Top2a 
and Top2b, follow an ATP-dependent procedure involving binding to the DNA-double 
strand, cutting both strands transiently, pushing the second double-stranded DNA 
segment through the break, and finally religating both segments (McClendon & Osheroff, 
2007; Wang, 2002). 
 Coordinated action of type I and type II topoisomerases relieves topological 
perturbations arising from DNA replication and gene transcription (Mondal & Parvin, 
2001; Wang, 2002). As the replication machinery advances along the double-stranded 
DNA, negative and positive supercoils form at the back and front of the machinery 
2 
 
(Figure 1). Top2a resolves the tangled duplex molecules and alleviates the supercoils 
(Figure 1). Also, Top2a enzymes are key players in resolving supercoils resulting from 
transcription (McClendon, Rodriguez, & Osheroff, 2005; Mondal & Parvin, 2001). 
 
Figure 1. Topoisomerase II alpha relieves topological stress in DNA.  As the 
replication machinery moves along the DNA, negative (under-winding) and positive 
(over-winding) supercoils form towards the back and front of the replication fork, 
creating topological DNA stress. Top2a is required to relax the tension and untangle the 
over-lapping double-stranded DNA segments. A similar process occurs during 
transcription as the RNA machinery moves along the DNA. 
 
 Top2a, identified as a major component of the mitotic chromosome scaffold 
(Earnshaw, Halligan, Cooke, Heck, & Liu, 1985), is indispensable for cell proliferation.  
The expression of Top2a is increased in S phase, and peaks during M phase of the cell 
cycle (Heck, Hittelman, & Earnshaw, 1988; Woessner, Mattern, Mirabelli, Johnson, & 
Drake, 1991). Top2a is over-expressed in numerous cancer cell lines and tumors (Al-
Kuraya et al., 2007; Schrader et al., 2004; Willman & Holden, 2000; Zhao, Yu, Liu, 
Wang, & Cai, 2008). Therefore Top2a has been a clinical target in cancer therapeutics 
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and several groups of drugs have been developed.  Classes include DNA synthesis 
inhibitors or fluoroquinolones, DNA replication intercalators or anthracyclins such as 
doxorubicin, and others (Wong, Oliver, & Linington, 2012). Inhibitors of mammalian 
topoisomerases, such as camptothecins, etoposide, tenoposide, doxorubicin, are also 
cytostatic drugs for cancer treatment (Pommier, Leo, Zhang, & Marchand, 2010). 
Inhibition of topoisomerase II activity by drugs such as etoposide and doxorubicin causes 
cell cycle arrest in late S and G2 phase (Garrett & Collins, 2011). 
 
Linker Histone H1: In a Nutshell 
In eukaryotes,  147 base pairs of DNA  are wrapped around the octameric core 
histone molecules, including two copies of H2A, H2B, H3, and H4, to form the 
nucleosome (Brown, 2003; Happel & Doenecke, 2009; Horn & Peterson, 2002; Luger, 
Mader, Richmond, Sargent, & Richmond, 1997; Zlatanova, Bishop, Victor, Jackson, & 
van Holde, 2009). Linker histone H1 binds to nucleosome at the entry and exit sites of 
DNA as well as the linker DNA, facilitating the folding of higher order chromatin 
structure (Figure 2) (Happel & Doenecke, 2009; Wolffe, Khochbin, & Dimitrov, 1997). 
This binding of H1 also stabilizes the 30 nm fiber (Bednar et al., 1998; Robinson & 
Rhodes, 2006; Sumner, 2003; Woodcock, Skoultchi, & Fan, 2006), which can be further 
compacted into 100 and 400 nm interphase fibers.  
Linker histone H1 is a family of lysine-rich proteins that has a canonical three 
domain structure. The tripartite structure includes a highly conserved globular domain 




Figure 2. Structure and function of linker histone H1.  Linker histone H1 is composed 
of a tripartite structure with an N-terminal domain (NTD), a globular domain (GD), and a 
C-terminal domain (CTD). The first level of chromatin condensation involves the 
wrapping of the double stranded DNA around an octamer of core histone molecules 
(H2A, H2B, H3, and H4) to form the nucleosome. H1 binds to the nucleosomal DNA and 
the linker DNA. 
 
aa), and a short basic N-terminal domain (NTD: ~13-45 aa) (Happel & Doenecke, 2009). 
The CTD is intrinsically disordered, and its chromatin condensing function and 
interaction with linker DNA depends on its amino acid sequence (Caterino, Fang, & 
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Hayes, 2011; Hansen, Lu, Ross, & Woody, 2006; Lu, Hamkalo, Parseghian, & Hansen, 
2009). GD contains winged-helix motifs and DNA binding sites, and interacts with the 
nucleosome (Ramakrishnan, Finch, Graziano, Lee, & Sweet, 1993; Thomas, 1999). Both 
the GD and the CTDs also function in protein-protein interaction (Montes de Oca, Lee, & 
Wilson, 2005; Widlak et al., 2005). However, the roles of the NTD in DNA-binding 
remain unknown (Harshman, Young, Parthun, & Freitas, 2013; McBryant, Lu, & Hansen, 
2010). 
 11 different H1 variants have been identified in mammals, making it the most 
divergent class of histones (Happel & Doenecke, 2009). In humans, there are one oocyte-
specific variant (H1oo), three testes-specific subtypes (H1t, H1T2 and HILS1), and seven 
somatic isoforms (H1.1-H1.5, H1.0, and H1x) (Albig, Kardalinou, Drabent, Zimmer, & 
Doenecke, 1991; Albig, Meergans, & Doenecke, 1997; Happel & Doenecke, 2009; 
Medrzycki, 2013; Meergans, Albig, & Doenecke, 1997; Th'ng, Sung, Ye, & Hendzel, 
2005). The different subtypes have distinctive nucleosomal binding affinities (Misteli, 
Gunjan, Hock, Bustin, & Brown, 2000), so may differentially modulate chromatin 
compaction (Brown, 2001; Oberg, Izzo, Schneider, Wrange, & Belikov, 2012; Th'ng et 
al., 2005). In addition, expression of the different subtypes is not the same. Among the 
somatic H1s, the expression of H1.0 and H1x is replication-independent, whereas the 
expression of H1.1 through H1.5 is dependent on replication (Albig et al., 1997). The 
levels of H1 subtypes differ in dividing and non-dividing cells. While H1.0 accumulates 
in cells that are terminally differentiated, the other somatic H1s are ubiquitously 
expressed with varying levels (Happel & Doenecke, 2009). 
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 Regulatory functions of linker histones include inhibiting the action of chromatin-
assembly complexes, modulating the access of regulatory factors and chromatin-specific 
proteins to their chromatin targets, and restricting the mobility of the nucleosome 
(Harshman et al., 2013; McBryant et al., 2010; Millan-Arino et al., 2014). In addition to 
its role in stabilization and condensation of chromatin, H1 functions in specific regulation 
(repression and activation) of gene expression (Fan et al., 2005; Happel & Doenecke, 
2009; Woodcock et al., 2006). H1 depletion in mouse embryonic stem cells alters the 
global chromatin structure but regulates specific gene expression (Fan et al., 2005). H1 
also influences developmental processes in C. elegans (Jedrusik & Schulze, 2001). In 
mice, depletion of individual linker histone H1 variants does not hinder development and 
show no obvious phenotype, due to the compensatory up-regulation of other subtypes 
(Fan, Sirotkin, Russell, Ayala, & Skoultchi, 2001; Sirotkin et al., 1995). However, triple 
H1 (H1c, H1d, and H1e) knockout studies prove H1 to be indispensable for mammalian 
development (Fan et al., 2003).  
 Individual H1 variants may function through protein-protein interactions 
(McBryant et al., 2010). For example, the replacement variant, H1.0, is likely a vital 
player in the nucleolus, as it is reported to interact with extensive protein networks in 
nucleolus, involving RNA metabolism, pre-mRNA splicing, rRNA biogenesis, 
translation, and cellular transport (Kalashnikova et al., 2013). H1.1 has been shown to 
interact with Barrier-to-autointegration factor (BAF), which may provide access to 
chromatin (Montes de Oca et al., 2005). H1.2 has been found to repress p53 target genes 
by forming complexes with p53, the tumor suppressor (K. Kim et al., 2012), and H1.4 
was found to recruit heterochromatin protein 1 (HP1) and Polycomb complexes which 
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lead to gene silencing (Daujat, Zeissler, Waldmann, Happel, & Schneider, 2005). H1 is 
also involved in apoptosis by interaction with DNA fragment factor 40/Caspase activated 
DNase (DFF40/CAD) (Liu, Zou, Widlak, Garrard, & Wang, 1999; Widlak et al., 2005). 
 Previous studies in our lab have identified Top2a as a novel H1.3 binding partner 
by co-immunoprecipitation in FLAG-H1d-containing embryonic stem cells (Lasater, 
2012). Further studies have shown that mouse histone H1 inhibits Top2a activity in vitro 
and that overexpression of its human homolog (hH1.3) in human cancer cells leads to 
increased cell proportion with defects in chromosome segregation in vivo (Lasater, 2012). 
 In this thesis, we analyzed H1 profiles in a human cervix adenoma cancer cell 
line, HeLa cells, and investigated the effects of H1.3 overexpression on cell growth and 
mitotic chromosomes in these cells. Our results suggest a regulatory role of H1 in 
chromosome function through inhibition of Top2a.  These results might lead to a new 








HeLa cells (human cervical cancer-derived cell-line) were cultured at 37°C and 
5% CO2 in Minimum Essential Medium Alpha Medium (Gibco, Grand Island, New 
York) supplemented with 10% Fetal Bovine Serum (FBS; Thermo-Scientific, Waltham, 
Massachusetts) and 1% penicillin-streptomycin (Corning, Manassas, Virginia). Cell 
media were changed every 2 days and cells were passaged when they reach about 80% 
confluency.  HeLa/hH1.3 and HeLa/EV stable cell lines, established by transfecting HeLa 
cells with FLAG-hH1.3 expression vector and empty vector respectively, were cultured 
with medium supplemented with G418 (1 mg/ml). Transfection of HeLa cells were 
performed using Lipofectamine 2000 (Invitrogen, Carlsbad, California) according to the 
manufacturer’s recommendations.  HeLa/hH1.3 cell lines were established by previous 
lab graduate Samantha Lasater (Lasater, 2012). 
Growth Curve and MTT Assay 
The growth curve and MTT assays were performed in parallel to measure cell 
growth and metabolic activity, respectively. For the growth curve assay, 30,000 cells 
were seeded per well on a 12-well plate (Corning) in triplicates, with each cell line 
cultured in 24 wells total. Cells were trypsinized and counted every two days for 12 days.  
For the MTT assay, exponentially growing cells were seeded in triplicates at a 
density of 1,500 cells in 0.1 ml medium per well on a 96-well plate.  For each 
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measurement, 11 μl of 5mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltatrazolium bromide) was added the wells to be analyzed and the plate is 
incubated at 37°C for 2 hours to allow the reduction of the yellow tetrazole and formation 
of purple formazan crystals. Then, 111 μl stop solution (for 50 ml: 25 ml 20% SDS; 50 μl 
37% HCl; ddH2O) was added and the plate was incubated overnight at 37°C. The 
absorbance is then read at 570 nm with a micro-plate reader. The acellular wells were 
included as blank negative controls in the template. The average absorbance were 
calculated, and plotted to determine the metabolic activity. 
Nuclei Purification 
When ready to harvest, HeLa cells grown in 15 cm plates (Corning, Manassas, 
Virginia) were washed with 1xPBS (0.001 M phosphate buffer; 138 mM NaCl; 3 mM 
KCl; pH 7.4), harvested, and pelleted by centrifugation at 1,500 rpm for 10 minutes at 
4°C. The pellet was resuspended in 1xPBS and centrifuged again at 1,500 rpm for 3 
minutes. The pellet was subsequently resuspended in RSB Buffer (10 mM NaCl; 3 mM 
MgCl2; 10 mM Tris pH 7.5) at 10
7
 cells/ml, and dounced on ice for 20 minutes with an 
equal volume of RSB buffer containing 0.5% NP-40, 0.5 mM PMSF, and 10 μl 
cOimplete Protease Inhibitor (PI) (Rocher, Indianapolis, IN) per 10
7
 cells, counted, and 
centrifuged at 1,100 rpm for 7 minutes at 4°C. Next, pellets were resuspended in 500 μl 
RSB/10
8
 cells with 0.5 mM PMSF and PI. The nuclei can used for nuclear extract 
preparation or stored at -80°C in 1:1 glycerol to storage buffer (50 mM Tris pH 8.3; 40% 




Nuclei Extract Preparation 
Purified HeLa nuclei were centrifuged at 1,800 rpm for 5 minutes at 4°C. After 
removing the storage buffer, the pellet of nuclei was resuspended with 400 μl/10
8
 cells of 
buffer C (20 mM HEPES pH 7.9; 0.42 M NaCl; 5 mM MgCl2; 0.1 mM EDTA; 20% 
glycerol; 1% Triton-X-100; 1 mM DTT; 0.2 mM PMSF; PI). The tubes were rotated at 
4°C for 20 minutes and checked every 5 minutes to prevent clumping, centrifuged at 
1,200 g for 5 minutes at 4°C. The supernatant was transferred into dialysis cassettes 
(Thermo Scientific, Rockford, IL), dialyzed for 2 hours at 4°C in buffer D (20 mM 
HEPES pH 8.0; 20% (V/V) glycerol; 100 mM KCl; 0.2 mM EDTA; 1 mM DTT; 0.5 mM 
PMSF), subsequently transferred into new tubes, and stored at -80°C. 
Western Blotting 
Total protein concentration of each sample was measured using the Bradford 
Protein Assay (BioRad Life Sciences, Hercules, California). Samples were then 
denatured in 4x SDS loading dye (200 mM Tris-Cl (pH 7.0); 400 mM DTT; 8% SDS; 
20% glycerol) and incubated at 95°C for 3-5 minutes before loading on 10% SDS-
Polyacrylamide gels. Proteins were separated at 100 volts for 1.5 hours and transferred to 
a 0.45μm nitrocellulose membrane (BioRad Life Sciences, Hercules, California). 
Membranes were blocked with 1:1 ratio of Odyssey blocking buffer (Li-Cor Inc., 
Lincoln, Nebraska) and 1xPBS for 1 hour at room temperature followed by incubation 
overnight with primary antibodies (table 1) at 4°C with gentle shaking. The membranes 
were subsequently washed with 0.1% Tween-20 in 1xPBS (PBS-T) and incubated with 
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secondary antibodies for 1 hour (table 1). Blots were washed with PBS-T and visualized 
using Odyssey Infrared Imaging System (Li-Cor Inc., Lincoln, Nebraska). 
Table 1. List of Primary and Secondary Antibodies 
Primary 
Antibody 
Species Company Dilution 
Anti-Top2a Rabbit TopoGEN, Port Orange, Florida 1:10,000 
Anti-FLAG Mouse Sigma-Aldrich, Saint Louis, Missouri 1:1,000 
Anti-H1.0 Rabbit abcam, Cambridege, Massachusetts 1:1,000 
Anti-H1.1 Rabbit abcam, Cambridege, Massachusetts 1:1,000 
Anti-H1.2 Rabbit abcam, Cambridege, Massachusetts 1:1,000 
Anti-H1.3 Rabbit abcam, Cambridege, Massachusetts 1:1,000 
Anti-H1.4 Rabbit abcam, Cambridege, Massachusetts 1:1,000 
Anti-H1.5 Rabbit abcam, Cambridege, Massachusetts 1:1,000 
Secondary 
Antibody 









-  Life Technologies, Carlsbad, California 1:10,000 
Goat anti-
Rabbit 
-  Life Technologies, Carlsbad, California 1:10,000 
 
Top2a In-Vivo Link Assay 
HeLa/H1.3(H) cells growing in exponential phase were probed for Top2a 
inhibition using the Topoisomerase II In Vitro Link Kit (TopoGEN, Port Orange, 
Florida). According to the manufacturer’s manual, cells were treated with 100 μM 
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etoposide. After incubation for 30 minutes at 37°C in 1 ml serum-free medium, cells 
were counted then lysed by 1% sarkosyl. The lysate was carefully layered on top of a 
cesium chloride (CsCl) gradient. The polyallomer tubes were then centrifuged at 31,000 
RPM for 12 hours at room temperature. Fractions of 0.4 ml each were collected and 
diluted for OD measurement and identification of Top2-DNA cleavage complexes at 260 
nm. The different CsCl fractions were loaded on a nitrocellulose membrane and subjected 
to vacuum in a slot blot device. Membrane was then incubated with blocking buffer in 
PBS-T for 2 hours. After western blotting using Top2a antibody, signals were detected 
using the Odyssey Imaging System (LiCor Biosciences). 
Histone Extraction and Purification 
Histone extraction and purification were performed as previously described 
(Medrzycki, Zhang, Cao, & Fan, 2012). Briefly, HeLa cultured in 15 cm plates were 
harvested and resuspended in 3 ml sucrose buffer (0.3 M sucrose; 15 mM NaCl; 2 mM 
EDTA; 10 mM HEPES pH 7.9; 0.5 mM PMSF; PI) with 0.5% NP-40, and dounced on 
ice with a B pestle (Dounce homogenizer) for 10 minutes. Next, the homogenate was 
centrifuged at 1,575 g for 10 minutes at 4°C after which the pellet is resuspended in 1 ml 
high salt buffer (0.35 M KCl; 10 mM Tris pH 7.2; 5 mM MgCl2; 0.5 mM PMSF; PI) and 
dounced on ice. The homogenates were transformed into eppendorf tubes, incubated on 
ice for 20 minutes, and centrifuged for 10 minutes at 14,000 rpm, 4°C. The pellet was 
resuspended in 0.4 ml 0.2N H2SO4 (1N=0.5M) using an eppendorf tube pestle dounce 
and incubated on rotator at 4°C overnight. The following day, the tubes were centrifuged 
at 14,000 rpm for 10 minutes at 4°C, and the supernatant was transferred into a new tube. 
Since ample amount of protein was present, 2.5 V of ice cold 100% ethanol was added 
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directly to the tube, mixed and stored overnight at -20°C. The tubes were centrifuged at 
14,000 rpm for 10 minutes at 4°C, and the histone pellet was washed 3 times with 70% 
ethanol, and air-dried. The resulting pellet was stored at -80°C or used for HPLC 
analysis. 
HPLC analysis of Histones 
HPLC analysis of linker histone H1 subtypes was performed as previously 
described (Fan & Skoultchi, 2004; Medrzycki et al., 2012). Briefly, histone extracts from 
HeLa and HeLa/H1.3(H) were resuspended in 100μl ddH2O and injected into a Vydac 
218TP C18 reverse-phase column (Grace Davison Discovery Sciences, Deerfield, 
Illinois) of the GE AKTA Purifier HPLC system (GE Healthcare Life Sciences, 
Pittsburgh, Pennsylvania). Linker and core histones were fractionated with an increasing 
acetonitrile gradient with 0.1% Trifluoroacetic acid (TFA) over time as shown in table 2. 
The effluent was monitored at 214 nm, and histone peaks were collected according to the 
histone profiles (table 2 & Figure 3). UNICRON 5.11 Software (GE Healthcare Sciences, 
Pittsburgh, Pennsylvania) was used to record and analyze the HPLC profiles. All protein 
fractions collected were lyophilized and resuspended in ddH2O for further analysis. The 
HPLC peaks were collected and analyzed on a Qstar XL MS/MS system (Applied 
Biosystems) with ESI (Electronspray ionization). The Mass Spectrometry data were 
analyzed by Mass Spectrometry Analyst QS software (Applied Biosystems). 
Identification of histone subtypes attributed to the relative peaks was also confirmed 
using Western blot. The relative proportions of H1 subtypes as well as the ratio of H1 
subtypes to nucleosome core particles were calculated from the normalized A214 values 
of the peaks for the H1 subtypes and H2B of HPLC analysis.  A214 values were 
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normalized by the number of peptide bonds of the respective histone proteins. The ratios 
of the percentage of total H1 and the total H1 per nucleosome ratios were calculated as 
follows. 
                      
                                    
                                    
 
                      
 
 
                                     
                     
 
Table 2. Acetonitrile gradient for HPLC analysis 
Time (Minutes) Acetonitrile / 0.1% TFA (%) 0.1% TFA / ddH2O (%) 
0 0 100 
1 5 95 
11 25 75 
26 30 70 
45 35 65 
66 40 60 
75 43 57 
126 55 45 
131 90 10 




HeLa cells were grown on glass cover slips in required media (EMEMα) till 
confluency. Cells were fixed with 4% paraformaldehyde in PBS for 20 minutes followed 
by permeabilization with 0.2% Triton X-100 in PBS for 30 minutes at room temperature. 
After washing with 1xPBS, cells were incubated with 10% FBS in PBS overnight. For 
immunocytochemistry, individual cover slips were incubated with primary antibodies 
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(Top2a, 1:10,000; M2-FLAG, 1:400) diluted in 10% FBS in PBS for 1 hour in the dark. 
The coverslips were washed with 0.2% Tween-20 in PBS then incubated with 
fluorescently labeled secondary antibodies (Goat anti-rabbit, 1:200; Donkey anti-mouse, 
1:500) diluted in 10% FBS in PBS for 1 hour in the dark. Nuclei were counter stained 
with Hoechst dye (1:1,000). After washing with 0.2% Tween-20 in PBS, cells were 
mounted on a slide using Fluormount G and images were collected on an Olympus 
Fluorescence Microscope (Olympus America Inc., Center Valley, Pennsylvania) and 
processed by Q Capture Pro software version 5.1 (Q imaging, Surrey, British Colombia, 
Canada). 
Metaphase Spread 
HeLa cells growing in log phase were treated with colcemid (Life Technologies, 
Carlsbad, California) at 37°C for 60 minutes when 85% confluence, trypsinized, 
harvested, centrifuged at 900 rpm for 4 minutes at room temperature, resuspended in 
1xPBS and centrifuged again at 900 rpm for 4 minutes at room temperature. Cells were 
subsequently resuspended with pre-warmed hypotonic solution (75 mM KCl), incubated 
at 37°C for 7 minutes, and fixed as was previously described (Zhang et al., 2012). After 
fixation, cells were concentrated and dropped onto an angled, humidified microscope 
slide, dried, and stained with Hoechst dye (1:1,000) for 60 minutes in the dark. Images 
were taken at a 100x objective via an Olympus Fluorescence Microscope (Olympus 






RNA was extracted from HeLa and HeLa/H1.3(H) using TRIzol Reagent 
(Invitrogen, Carlsbad, California) according to the manufacturer’s protocol. Briefly, cells 
grown in monolayer were lysed (by adding 0.5 ml of TRIzol reagent) and homogenized. 
After incubation at room temperature for 5 minutes,     volume of chloroform was 
added and the tube were shaken vigorously for 15 seconds and incubated at room 
temperature for 2-3 minutes.  The mixtures were subsequently centrifuged at 12,000 g for 
15 minutes at 2-8°C, the RNA-containing colorless aqueous phase was transferred into a 
fresh tube, and     volume of isopropanol was added. After incubation at room 
temperature for 10 minutes, RNA was pelleted by centrifugation at 12,000 g for 10 
minutes, and the pellet was washed with 75% ethanol, 95 % ethanol, air dried, and 
dissolved in RNase-free water. The RNA concentration was measured using Nanodrop 
1000 (Thermo Scientific, Wilmington, DE) and gel electrophoresis was performed to 
determine RNA quality.  
Quantitative Reverse Transcription PCR (qRT-PCR) 
The synthesis of the first-strand cDNA from 2.5 μg total RNA extracted from 
HeLa cells was performed using the SuperScript III (SSIII) First-Strand Synthesis System 
for RT-PCR (Invitrogen, Carlsbad, California) according to the manufacturer’s protocol. 
Briefly, RNase-free water and RNA were added to a 2:1:1 ratio of dNTP to random 
hexamers (random primers) and oligodT respectively for a total of 1 μl per tube. The mix 
was incubated for 5 minutes at 65°C, then placed on ice for 1 minute. For the cDNA mix, 
5x Buffer was added to 0.1 M DTT, SSIII RT (200 U/μl), and RNaseOUT (40 U/μl). This 
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cDNA mix was added to each RNA/primer mix. Using a PCR machine, the total reaction 
mixture (10 μl total per reaction) was carried out at 25°C for 10 minutes, followed by 50 
minutes at 50°C, 5 minutes at 85°C, and chilled on ice. The resulting cDNA were 
immediately used for qRT-PCR or stored at -20°C for future use.  
 The cDNA was analyzed by quantitative real-time PCR as previously described 
(Medrzycki, 2013). PCR primers used for quantitative analysis of the different FLAG-H1 
subtypes were developed by a PhD graduate from our lab, Dr. Magdalena Medrzycki, and 
are listed in table 3. iQ SYBR green PCR Supermix kit (BioRad, Hercules, California) in 
a MyIQ Single Color RT-PCR detection system was used to quantify and analyze the 
amounts of cDNA from both HeLa and HeLa/H1.3(H). Samples were loaded on a 
Microseal 96-well PCR plate (BioRad) and analyzed in duplicates. For this experiment, 
the following program was applied: 3 minutes at 95°C; followed by 40 cycles of 10 
seconds at 95°C, 20 seconds at 60°C, 30 seconds at 72°C; and ended with 1 minute at 
95°C. Then iQ5 Optical System software version 2.0 supplied by the manufacturer was 
used to record and quantify the expression levels of the different genes. The expression 
levels of the FLAG-H1 genes were normalized against those of a house-keeping gene, 
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase), and graphs of the relative 
































An unpaired two-tailed student’s t-test with 95% confidence intervals was 
performed and graphs were generated using Microsoft Excel 2010 software (Microsoft 







3.1 Analysis of the differential expression patterns of individual linker histone H1 
variants in HeLa and HeLa/H1.3(H) cells 
HeLa is an immortal cancer cell line derived from cervical cancer and is 
frequently used in cancer research. To quantitatively measure the expression patterns of 
individual linker histone H1 subtypes in HeLa cells, we performed RP-HPLC of total 
histones extracted from HeLa cells. The different linker histone variants were separated 
based on their hydrophobicity on HPLC following an increasing gradient of 
acetonitrile/0.1% TFA as described in Materials and Methods. HPLC profiles displayed 
two H1 peaks which were collected, lyophilized, and analyzed by Western blotting and 
Mass Spectrometry.  Such analyses indicated that the first peak contains H1.5 and second 
peak contains H1.2, H1.3, and H1.4 (Figure 3). 
 Previous studies from our lab have identified Top2a as a novel H1.3 binding 
partner and demonstrated that overexpression of H1.3 in HeLa cells leads to an increased 
cell proportion with chromosome bridges (Lasater, 2012).  To quantitatively assess the 
level of expression of H1 variants in HeLa/H1.3(H) cells (Lasater, 2012), we performed 
HPLC analysis of total histone extracts from HeLa/H1.3(H) cells.  Compared with HeLa 
cells, HeLa/H1.3(H) cells had an increased proportion of peak 2 and a decrease level of 
peak 1 in the HPLC profile (Figure 3A).  Western blotting assays show that FLAG-hH1.3 
was co-eluded with the endogenous H1.3 protein in the peak #2, indicating that 
exogenous H1.3s have the same biochemical properties as the endogenous.  Also, a 
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stronger band of FLAG-H1.3 than H1.3 in the second fraction was detected in Western 
blotting with anti-H1.3 antibody, reflecting a significantly higher amount of FLAG-H1.3 
compared to the endogenous counterpart (Figure 3B and Figure 4). The presence and 
significant amount of FLAG-H1.3 in the peak #2 was further confirmed by Mass 
Spectrometry analysis of proteins present in the peak #2 (Figure 3C).  qRT-PCR assays 
using primers specific to the FLAG-H1 variants as described in Materials and Methods 
also indicate the overexpression of FLAG-H1.3 and the lack of expression of other 
FLAG-H1 subtypes (Figure 5). 
 
Figure 3. Analysis of total histone extracts from HeLa and HeLa/H1.3(H) cells. (A) 
RP-HPLC analysis of total extracts from HeLa and HeLa/H1.3(H). (B) Western blot of 
Peak 1 and peak 2 eluted from HPLC.  (C) Mass spectrometry analysis of peak 2 eluted 





Figure 4. Western blotting analysis of total histone extracts from HeLa and 




Figure 5. qRT-PCR analysis of mRNA levels of FLAG-tagged linker histone 
subtypes in HeLa and HeLa/H1.3(H) cells. Gene expression levels of FLAG-H1s were 
normalized over that of GAPDH. 
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To quantify and compare the protein levels of individual H1 subtypes and the 
total H1s in HeLa and HeLa/H1.3(H) cells, we calculated H1 to nucleosome ratio 
according to the HPLC analysis (representative profiles shown in Figure 3A) as described 
in Materials and Methods. Such analysis showed that the total H1 to nucleosome ratios 
were 0.67 and 0.96 in HeLa and HeLa/H1.3(H), respectively.  These results indicate that 
overexpression of FLAGH1.3 leads to a 43% increase of the total H1 levels in 
HeLa/H1.3(H) compared with HeLa cells (Figure 6A). This increase is due to the 
overexpression of FLAGH1.3 which also leads to the reduced percentage of H1.5, and a 
likely decrease in levels of H1.2 and H1.4 among the total H1s (Figure 6B).  
 
Figure 6. Overexpression of linker histone H1.3 increases total H1 levels and 
changes H1 composition in HeLa cells.  The H1 to nucleosome ratio (A) and the 
percentage of total histone (B) of HeLa and HeLa/H1.3(H) cells were calculated as 
described in Materials and Methods. Results were obtained from three independent 






3.2 Top2 co-localizes with linker histone H1 in vivo 
Previous co-immunoprecipitation and western-blot data from our lab have shown 
that histone H1.3, the most abundant H1 variant in mouse ESCs (Fan et al., 2005), 
interacts with Top2a in vivo ((Lasater, 2012) and Xu and Fan, unpublished observation). 
To further investigate the cellular localization of H1 and Top2a, we performed 
immunostaining of HeLa/H1.3(H) cells using anti-FLAG and anti-Top2a antibodies as 
described in Materials and Methods. The results indicate a co-localization of H1 and 
Top2a in the nucleus (Figure 7), further supporting the interaction of H1 and Top2a in 
vivo.  
 
Figure 7. Top2a co-localizes with H1 in vivo. Scale bar: 10μm 
 
 
3.3 Over-expressing hH1.3 in HeLa cells leads to increased cell population with 
abnormal chromosomes 
Top2a is essential for chromatin disentanglement, separation of sister chromatids, 
and chromosome condensation (Baxter & Aragon, 2012; Gonzalez et al., 2011; Li et al., 
2013; Samejima et al., 2012). Since we previously demonstrated that H1 inhibits Top2a 
activity (Lasater, 2012), we set out to compare the mitotic chromosome morphologies of 
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HeLa and HeLa/H1.3(H) cells. Cells arrested at metaphase using colcemid and 
metaphase spreads of each of the cell lines were prepared as described in Materials and 
Methods. The majority of cells had normal mitotic chromosomes morphology with 
distinct and condensed chromosomes, while a small fraction of cells displayed abnormal 
chromosome morphology with long, entangled or uncondensed chromosomes (Figure 
8A). We observed a significantly higher percentage of undercondensed and entangled 
chromosomes from the metaphase spreads of HeLa/H1.3 cells compared to those from 
HeLa or HeLa/EV control cell lines (Figure 8B).  Results from three independent blind-
counting experiments (75 metaphase spreads per cell line per experiment) demonstrated 
that HeLa and HeLa/EV cells (HeLa cells transfected with an empty vector) had 
respective 12.94% and 9.35% of cells with abnormal chromosomes morphology 
compared with 28.40% and 21.07% of respective HeLa/H1.3(H) and HeLa/H1.3(M) cells 
These results suggest that H1.3 overexpression inhibits chromosome condensation and 
segregation, mimicking the abnormal mitotic chromosome morphologies observed in 
cells treated with Top2a siRNA and shRNA (Bower et al., 2010; Lane, Gimenez-Abian, 
& Clarke, 2013).  These results support an inhibitory role of H1 on Top2a, which likely 





Figure 8. Over-expressing hH1.3 in HeLa cells leads to increased cell population 
with abnormal chromosomes. (A) Representative metaphase spread images showing 
normal, entangled and undercondensed chromosomes. Scale bar: 10μm (B) Percent of 
cells with abnormal chromosomes of HeLa, HeLa/EV, HeLa/H1.3(M) and HeLa/H1.3(H) 
cells. P values were calculated using a student’s t-test analysis. 
 
 
3.4 Over-expressing hH1.3 in HeLa cells inhibits cell growth 
To further characterize the phenotypic changes resulting from over-expressing 
hH1.3 in HeLa cells, we analyzed growth rate and metabolic activity by growth curve and 
MTT assays. The MTT assay measures the ability of the mitochondrial enzyme, succinate 
dehydrogenase, to cleave the yellow tetrazolium salt to form the purple, water insoluble, 
formazan crystals. This reduction reaction in the mitochondria of living cells is an 
indicator of the viability and proliferative activity of the cells (Mosmann, 1983).  
HeLa/H1.3(H) cells displayed a slower growth rate and a decrease in metabolic activity 
compared to HeLa cells (p<0.0001) (Figure 9).  The doubling time during the exponential 
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growth phase (days 2-6) was calculated based on the cell numbers relative to the initial 
seeding (day 0).  HeLa had a doubling time of 23.60±1.33 hours, similar to the 24 hours 
reported in the literature (Stephenson, 1982), whereas HeLa/H1.3(H) cells had a doubling 
time of 27.75±1.68 hours (p<0.0001), a 16.18% increase, suggesting an inhibition on cell 
growth rate by H1.3 overexpression. HeLa/EV cells (HeLa cells transfected with empty 
vector) displayed no significant difference in growth curve and MTT assays from HeLa 
cells (data not shown).  
   
 
Figure 9. Over-expressing hH1.3 in HeLa cells leads to delayed growth and 
decreased metabolic activity (A) A graph showing the growth rate and (B) MTT assay 






3.5 H1 inhibition of Top2a does not proceed via the Top2a-DNA complex 
To investigate the mechanism of inhibition of Top2a by H1.3, we examine the 
production of DNA-Topo complexes using the topoisomerase in vivo link assay as 
described in Materials and Methods.  This assay resolves DNA-Top2 complexes on a 
CsCl gradient.  Different fractions collected from ultracentrifugation were measured for 
DNA content at OD260 and for Top2 levels using a dot blot and immunoblotting.  HeLa 
and HeLa/H1.3(H) cells were treated with etoposide, a topoisomerase inhibitor that 
stabilizes DNA-Top2 cleavage complexes and causes double-strand breaks (Pommier et 
al., 2010).  As expected, treatment with etoposide resulted in decreased cell numbers 
(Figure 10A).  HeLa cells treated with etoposide had a significant peak at fraction 11 
where high DNA content coincides with a strong Top2 signal, indicating the DNA-Top2 
complex (Figure 10B&C). However, HeLa, HeLa/H1.3(H), and  HeLa/H1.3(H)/etoposide 
cells did not show significant amount of DNA-Topo complex (Figure 10B&C). This 
suggests that H1 inhibition of Top2a is probably not through the DNA-Topo complex. In 
addition, HeLa/H1.3(H) cells treated with etoposide had a significant lower Top2-DNA 
complex peak than that of HeLa treated with etoposide, suggesting a possible competitive 
inhibitory effect of H1 with etoposide on Top2a.  Alternatively, this may suggest that the 




Figure 10. H1 inhibition of Top2a does not proceed via the Top2-DNA complex. (A) 
The number of HeLa and HeLa/H1.3(H) cells with and without treatment of 100uM of 
the topoisomerase II inhibitory drug etoposide (* p<0.05; ** p<0.01; *** p<0.001). (B) 
Absorbance at 260 nm of 27 collected fractions after ultracentrifugation with the Topo-
DNA and free protein peaks identified. (C) Representative images of Western blots of 





DISCUSSION AND CONCLUSION 
In this study, we have further investigated the inhibition of topoisomerase II alpha 
by linker histone H1. Previous studies from our lab have demonstrated the interaction 
with and inhibition of Top2a by H1 in vitro and also suggested a role of H1 in inhibiting 
Top2a activity in vivo. In this thesis, characterization of HeLa cells overexpressing hH1.3 
provides additional evidence supporting an interaction with and inhibition of Top2a by 
linker histone H1.  Furthermore, we found that overexpression of hH1.3 significantly 
suppressed the growth and metabolism of HeLa cancer cells and resulted in an increased 
cell population with abnormal mitotic chromosomes.  Combining these results with our 
previous studies, we propose a working model in which inhibition of Top2a activity by 




Figure 11. Working Model of the interaction of H1 and Top2a and the effect of the 
inhibition on chromosome condensation and segregation 
  
When it comes to chromatin structure and function, numerous studies illustrated 
that Top2a plays a key role in chromosome compaction and the maintenance of a 
condensed conformation during mitosis (Chang, Goulding, Earnshaw, & Carmena, 2003; 
Downes et al., 1994; Maeshima & Laemmli, 2003). Similarly, linker histone H1 is a 
major contributor for chromosome compaction. When H1 was depleted in Xenopus laevis 
egg extracts, and when Top2a was inhibited in Indian Muntjac mammalian cells, 
chromosomes were prevented from properly aligning at the metaphase plate (Downes et 
al., 1994; Maresca, Freedman, & Heald, 2005). This inhibition of Top2a resulted in a 
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considerably thinner and longer chromosome morphology (Downes et al., 1994; Maresca 
et al., 2005). Here, we found a statistically significant increase of the undercondensed and 
entangled chromosomes when hH1.3 was overexpressed in HeLa cells (Figure 8). This 
may be due to the inhibitory effects of hH1.3 on Top2a activity.  Future studies of Top2a 
knockdown experiment on hH1.3 cells would help determine if the increase in the 
abnormal chromosomes is due to the inhibitory effects of hH1.3 on Top2a or caused by 
other functions of H1.3.   
 As a follow up on the possible mechanism of the inhibition, we found that H1 
does not inhibit Top2a via a DNA-Topo complex measured by the topoisomerase II in 
vivo link assay.  Etoposide, a commonly used inhibitor of eukaryotic Topo II, covalently 
attaches to DNA and prevents the religation by Topo II, thereby resulting in DNA 
double-strand breaks (Baldwin & Osheroff, 2005; Favoni & Florio, 2011; Ross, Rowe, 
Glisson, Yalowich, & Liu, 1984). In the topoisomerase II in vivo link assay, etoposide 
treatment leads to significant enrichment of DNA-Top2 complex in HeLa cells but not in 
HeLa/H1.3(H) cells, suggesting that H1.3 may interact with and inhibits Top2a prior to 
Top2a binding to the DNA to resolve the supercoils during DNA replication. This 
possibility could be tested using chromatin immunoprecipitation to determine the 
genomic localization of H1.3 and Top2 in these cells. 
 In this study, we demonstrate that overexpression of H1.3 inhibits HeLa cell 
growth.  To further ascertain the inhibitory effects of H1.3 on HeLa cells is due to H1.3 
overexpression, knockdown of H1.3 in HeLa/H1.3(H) cells could be performed to 
determine the rescue of the cell growth phenotypes. In addition, further study of the cell 
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cycle profiles of HeLa/H1.3(H) and HeLa cells could refine our understanding of the 
mechanism of inhibition on cell growth by H1.3.  
 Inhibition of Top2a by synthetic molecule induces cell cycle arrest in different 
human cancer cells (Belluti et al., 2013; Cheng et al., 2012; S. O. Kim et al., 2013; 
Olszewska, Szymanski, Mikiciuk-Olasik, & Szymanski, 2014). The inhibition of Top2a 
enzymatic activity can also trigger G2 checkpoint and deletion of Top2a leading to 
apoptosis (Akimitsu, Adachi, et al., 2003; Akimitsu, Kamura, et al., 2003; Luo et al., 
2009; McPherson & Goldenberg, 1998; St Pierre, Wright, Rowe, & Wright, 2002).  
Although a number of topoisomerase II inhibitors, such as etoposide, have been 
developed for cancer treatment, they often cause DNA damages to cancer cells and 
normal neighboring cells as well. The DNA-damaging effect often leads to secondary 
neoplasms in patients.  Therefore, new Top2a inhibitors with higher efficiency, 
specificity, and selectivity are desired. Our finding on the inhibition of Top2a by H1 
could lead to developing new Top2a inhibitors, such as peptide inhibitors for Top2a 
based on H1. It is highly possible that specific regions of H1, such as a specific H1 
domains or subdomains, may be sufficient for Top2a inhibition. In addition, testing on 
other cancer cell lines is warranted to determine the scope of the inhibitory effects on 
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